Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.

A similar statistically significant negative correlation was not seen following treatment with placebo ( r =−0.188, P =0.28) (Figure 2 ), though the difference between the correlation coefficients for ranolazine and placebo did not reach statistical significance (2‐tailed P =0.35 utilizing the above correlation r values and n=35 for each treatment group).

also in 111,027 other papers